Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Timothy Rolph files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Andrew Cheng - $2.99M of AKRO open-market activity in the last 12 months
- Jonathan Young - $1.20M of AKRO open-market activity in the last 12 months
- William Richard White - $28K of AKRO open-market activity in the last 12 months
- Catriona Yale - $28K of AKRO open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Timothy Rolph?
Timothy Rolph is a corporate insider, tracked as Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO). InsiderAlpha holds 12 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Timothy Rolph last file a Form 4?
The most recent primary Form 4 on record is dated 9 December 2025, one of 12 filings going back to 2024.
Has Timothy Rolph been buying or selling stock?
Recorded transactions: 0 open-market purchases and 13 open-market sales ($2.67M) across all tracked filings.
Where can I see all of Timothy Rolph's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Timothy Rolph and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
